# OnCo record paediatric-oncology-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/paediatric-oncology-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "paediatric-oncology-roadmap" ;
  schema:name "Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first"@en ;
  schema:description "Children's cancers were made curable by decades of cooperative trials that refined chemotherapy dose by dose. The next gains come from immunotherapy and targeted drugs built for children's cancers, from laws that stop companies skipping children, and from protecting the child who is cured from the cost of the cure."@en ;
  schema:url <https://onco.cc/roadmaps/paediatric-oncology-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.accelerate-platform.org/paediatric-strategy-forums/>, <https://ccss.stjude.org>, <https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer> ;
  onco:related <https://onco.cc/collections/alexs-lemonade-stand/>, <https://onco.cc/collections/st-baldricks/>, <https://onco.cc/ideas/idea-bio2-paediatric-first-development/>, <https://onco.cc/ideas/idea-tr2-paediatric-combo-prea/>, <https://onco.cc/ideas/idea-reg-single-paediatric-plan/>, <https://onco.cc/ideas/idea-reg-orphan-designation-reciprocity/>, <https://onco.cc/ideas/idea-fund-amc-paediatric-rare/>, <https://onco.cc/ideas/idea-fund-paediatric-deferral-escrow/>, <https://onco.cc/ideas/idea-data-paediatric-rwe-consortium/>, <https://onco.cc/ideas/idea-acc-childhood-medicines-platform-scale/>, <https://onco.cc/ideas/idea-acc-abandonment-stipends/>, <https://onco.cc/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/>, <https://onco.cc/ideas/idea-gd2-car-t-frontline-consolidation/>, <https://onco.cc/ideas/idea-bio1-fusion-tf-degraders/>, <https://onco.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://onco.cc/ideas/idea-moon-hearing-protection-cisplatin/>, <https://onco.cc/roadmaps/cell-therapy-roadmap/>, <https://onco.cc/roadmaps/survivorship-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/dipg-dmg/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/tandem-transplant/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/pdx-models/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/tovorafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/selumetinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/sodium-thiosulfate/>, <https://onco.cc/drugs/dexrazoxane/>, <https://onco.cc/drugs/mifamurtide/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/itcc/>, <https://onco.cc/companies/day-one-biopharmaceuticals/>, <https://onco.cc/companies/y-mabs/> ;
  onco:institutions <https://onco.cc/institutions/siop-europe/>, <https://onco.cc/institutions/accelerate-platform/>, <https://onco.cc/institutions/st-jude/>, <https://onco.cc/institutions/fda-oce/>, <https://onco.cc/institutions/ema/> ;
  onco:terms <https://onco.cc/terms/race-for-children-act/>, <https://onco.cc/terms/orphan-drug/>, <https://onco.cc/terms/accelerated-approval/> ;
  onco:trials <https://onco.cc/trials/int-0091/>, <https://onco.cc/trials/hr-nbl1/>, <https://onco.cc/trials/anbl0032/>, <https://onco.cc/trials/anbl0532/>, <https://onco.cc/trials/anbl1531/>, <https://onco.cc/trials/aren0533/>, <https://onco.cc/trials/acns0331/>, <https://onco.cc/trials/euramos-1/>, <https://onco.cc/trials/interfant-06/>, <https://onco.cc/trials/aaml0531/>, <https://onco.cc/trials/inter-b-nhl-ritux-2010/>, <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/tower/>, <https://onco.cc/trials/eliana/>, <https://onco.cc/trials/aall1731/>, <https://onco.cc/trials/gd2-cart01/>, <https://onco.cc/trials/pediatric-match/>, <https://onco.cc/trials/firefly-1/>, <https://onco.cc/trials/tadpole/>, <https://onco.cc/trials/action-dmg/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-incentive-misalignment/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/>, <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-trial-enrolment/> .